The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
GLR1990 - we don't know for sure but last year its PCR diagnostics was selling for 80-84% margin. Now obviously with other manufacturers on board and not just being produced by NCYT's own site (as demand is so great) we can assume the margins are slightly lower. However there is a caveat, from what we've seen NCYT have increased the price per kit by approx. over 40%, so I'd imagine the margins are largely intact. I think a fair assumption would be anywhere between 60-80% margin.
Chrishar, good post and I agree. Just to add on the competition from GDR/AVCT. I won't add ODX in that, as I see that as complimentary as its an antibody test. But on GDR/AVCT - GDR are 2-3 weeks from just applying for CE approval (never mind WHO, US FDA, FDA of Saudia Arabia, Indonesia, Phillipines, France etc etc that NCYT already have). AVCT CEO said he hopes to have the product by Mid-Summer - again then has to go through approvals etc. In a pandemic situation, and on AIM 1-2 months is an age. In that time NCYT will be shoring up further orders and contracts, growing their reputation and will have released Exsig to the market. Now I'm not saying GDR/AVCT will not do well - if I was to lean towards one it would be AVCT as their POC could do well along with antigen/antibody tests as we try to get countries back to normal, but they are many weeks away from knowing even how effective their products are. So as far as Mcap's go, I think they are currently overvalued at where they are (without finished products) , whilst I think NCYT is undervalued.
Yep don't think they'll get all 600+ samples back at once, they'll get them most probably in batches - I wouldn't be surprised if the first batch of results are already there that COBR and some lucky privy eyes that took part in the placing have already seen...
The fact that is this was the BOD and cornerstone investors smacks of letting people in cheap as they know the news is good. IMHO. May be wrong but that's was I'm smelling. Topped up 6k. Lets hope I'm right.
Interesting press reliease Sharedealer - that should help increase the potential for more PCR tests around the world. So should help NCYT's current PCR kit to increase volumes of kits produced as lack of reagents has been holding it back. However I still can't wait to here more on NCYT's new exsig, as that could truly revolutionise the amount of testing that could be achieved.
Seadoc, to be fair that's pretty cool, I did the Indonesian Islands in an old fishing trawler, broke down a few times, Captain then crashed in into a reef after having to much opium, stuck there for a whole day till the tide came in, then got involved in a few riots, the most bizarre adventure of my life, scary but great times and made me feel alive. Good on you, love adventures. Just close that short old boy. There's a good chap.
Never in doubt. First and best to market. Once you gain that reputation it will be hard for overs even if better to get a foot in. Good thing is at the moment is there is no-one better than NCYT. When some aim company sells £100m in a month and its mcap doesn't represent true value, never ever jump to other shares that promise the rainbow. This is delivering like no other aim share has ever done in such a short period. And that is a fact. Weird things happen in weird times, and people still can't get the head around the fact that these are extraordinary times where little companies like NCYT can keep on delivering in what normal circumstances would seem impossible.
How's you're French?
https://twitter.com/Zazaclubourso/status/1257769132302446592
Codey - NCYT doesn't draw blood for tests, that's antibody tests, swabs for PCR antigen tests. As to testing at airports, yep I don't see that at present as part of NCYT's scope. Just not feasible - that's where the POC tests come in. The way I see it there are 3 tests that will be needed - PCR, Antibody, and POC.
Breatheasy - tbh every person with any iota of intelligence in their wildest dreams predicted 45-50m sales in the last update, the fact that since the previous update is was upto 87m was 2x what most people couldn't have dared possible. The reason NCYT are initially upping to 8m is the same reason they upped from 250k - 2m, from 2-4m, from 4-8m is that there is so much demand for their test. The UK is great to have as its an Anglo-French company - but that is not their oyster - the world is . 100+ countries infact. Now wait for exsig to come out - at the moment they are building capacity to 8m - what do you think goes into making these tests - well let me give you a clue - most of it is in creating the reagents needed - exsig (d-pcr) requires substantially less reagents. What happens then to production - well a/ it becomes a lot cheaper b/it suddenly is easily to 2x, hell maybe 3x production from there even with the current manufactures on board. As to labs not being able to cope - again two things 1/Superlabs being set up 2/Exsig removes all the bottlenecks at these labs.
Just remember that Rock shot up from about 2m mcap to 12m mcap on just above average gold results - back then gold price was considerably lower. If Cobra find drill results are better, and now gold is much higher it gives you an idea of where this could go to in the short term.
gggg21 - that's great news if its opening today - expect a big amount spent talking about that in the daily briefing. Good chance that exsig will get mentioned and we'll get a nice RNS by tomorrow morning then.
In2win sounds like a born liar - only a couple of weeks ago he was asking this "When a placing is made what does this mean exactly?" on AST. He is an absolute newbie. Then he was deramping GDR questioning the validity of covid19 tests longevity less than a week ago....Kindly don't give this gentlemen the time of day..
Just listen to the CEO - where he says he expects Wudinna could have several million oz of gold resource.
https://audioboom.com/posts/7552598-podcast-no-15-with-craig-moulton-cobra-resources